We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

228 hedge funds and large institutions have $5.13B invested in Loxo Oncology, Inc in 2018 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 93 increasing their positions, 68 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 24

71% more call options, than puts

Call options by funds: $36.8M | Put options by funds: $21.6M

37% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 68

7% more funds holding

Funds holding: 213228 (+15)

0% more capital invested

Capital invested by funds: $5.11B → $5.13B (+$19.3M)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

Holders
228
Holders Change
+15
Holders Change %
+7.04%
% of All Funds
5.21%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.14%
New
41
Increased
93
Reduced
68
Closed
24
Calls
$36.8M
Puts
$21.6M
Net Calls
+$15.2M
Net Calls Change
-$2.31M
Name Holding Trade Value Shares
Change
Change in
Stake
California State Teachers Retirement System (CalSTRS)
76
California State Teachers Retirement System (CalSTRS)
California
$7.03M +$87K +518 +1%
Swiss National Bank
77
Swiss National Bank
Switzerland
$6.68M
Capital Fund Management (CFM)
78
Capital Fund Management (CFM)
France
$6M +$4.95M +29,482 +523%
Adage Capital Partners
79
Adage Capital Partners
Massachusetts
$5.98M -$5.04M -30,000 -46%
CM
80
Castleark Management
Illinois
$5.54M -$193K -1,150 -3%
NIP
81
Nicholas Investment Partners
California
$5.51M -$28.9K -172 -0.5%
New York State Common Retirement Fund
82
New York State Common Retirement Fund
New York
$5.47M +$101K +600 +2%
GH
83
GAM Holding
Switzerland
$5.16M +$454K +2,700 +10%
State of Wisconsin Investment Board
84
State of Wisconsin Investment Board
Wisconsin
$4.66M
Man Group
85
Man Group
United Kingdom
$4.65M +$343K +2,039 +8%
GC
86
Guggenheim Capital
Illinois
$4.6M +$277K +1,650 +7%
Barclays
87
Barclays
United Kingdom
$4.41M +$3.21M +19,082 +284%
AQR Capital Management
88
AQR Capital Management
Connecticut
$4.38M +$301K +1,790 +7%
TCM
89
Tekla Capital Management
Massachusetts
$4.2M +$2.39M +14,230 +137%
RhumbLine Advisers
90
RhumbLine Advisers
Massachusetts
$4.14M -$239K -1,424 -6%
Squarepoint
91
Squarepoint
New York
$4.03M +$3.31M +19,669 +504%
PAM
92
Panagora Asset Management
Massachusetts
$3.8M +$1.26M +7,471 +51%
MOACM
93
Mutual of America Capital Management
New York
$3.8M
PPA
94
Parametric Portfolio Associates
Washington
$3.71M -$855K -5,090 -19%
Royal Bank of Canada
95
Royal Bank of Canada
Ontario, Canada
$3.62M +$2.03M +12,104 +133%
Wells Fargo
96
Wells Fargo
California
$3.51M +$994K +5,916 +41%
MAP
97
Moody Aldrich Partners
Massachusetts
$3.43M -$799K -4,756 -19%
KCM
98
Kennedy Capital Management
Missouri
$3.06M +$3.02M +17,943 New
AIG
99
American International Group
New York
$3.05M +$92.3K +549 +3%
CCI
100
Columbus Circle Investors
$3.04M +$581K +3,457 +24%

LOXO Hedge Fund Activity: Q3 2018 in Review

228 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q3 2018, worth a combined $5.13B — up 0.38% from $5.11B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new LOXO positions and 24 closed out — a net gain of 17 holders — while 93 added to existing stakes and 68 trimmed.

The largest buyer was Eagle Asset Management, adding an estimated $48.9M. The largest seller was Aisling Capital, cutting an estimated $235M.

  • 228 institutional investors held Loxo Oncology, Inc (LOXO) as of Q3 2018, up from 213 in Q2 2018.
  • Funds reported $5.13B of Loxo Oncology, Inc stock for Q3 2018, up 0.38% quarter-over-quarter.
  • 41 funds opened new Loxo Oncology, Inc positions in Q3 2018 and 24 closed out, a net change of +17 holders.
  • The largest Loxo Oncology, Inc buyer in Q3 2018 was Eagle Asset Management, an estimated $48.9M added.
  • The largest Loxo Oncology, Inc seller in Q3 2018 was Aisling Capital, an estimated $235M sold.

Based on aggregated 13F filings for Q3 2018.